Trodelvy did not meet the primary endpoint of progression-free survival in the ASCENT-07 trial for HR-positive, HER2-negative metastatic breast cancer. An early trend favoring Trodelvy in overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results